Selection of the key articles and interviews published during the 2019 San Antonio Breast Cancer Symposium (SABCS)

By oncoXchange

December 18th 2019

0

 PIN


onx_sabcs2019_team_IMG_6799_hr.png#asset:16082

The oncoXchange news team spent 4 hectic days in San Antonio, Texas publishing articles and recording interviews with a number of key opinion leaders who presented important new data during the symposium. Here is a selection of some of the most noteworthy news items.



New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1

New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pre-treated with T-DM1Interview with: Ian E. Krop, MD, PhD


Polygenic Breast Cancer Risk Modification in carriers of High and intermediate Risk gene Mutations

Polygenic Breast Cancer Risk Modification in carriers of High and intermediate Risk gene Mutations. With: Allison W. Kurian, MD, MScInterview with Allison W. Kurian, MD, MSc


Activity of HER2 antibody-drug conjugate promising in breast cancer pretreated with T-DM1

article2_img_1200x627.png#asset:16081Article by Wayne Kuznar for oncoXchange


KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBC

KEYNOTE-522 - Neoadjuvant and Adjuvant Treatment with Pembrolizumab Improves PCR for TNBCInterview with Peter Schmid, MD, PhD


Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast CancerInterview with Luca Gianni, MD


Ribociclib/letrozole has high biological activity in luminal B breast cancer (CORALLEEN trial from SOLTI research group)

Ribociclib/letrozole has high biological activity in luminal B breast cancerArticle by Wayne Kuznar for oncoXchange